Evolving Treatment in Newly Diagnosed Multiple Myeloma Patients - Episode 8

Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM

November 20, 2024

Douglas Sborov, MD, discusses the most reported adverse events in transplant-eligible patients undergoing triplet or quadruplet therapy, as well as significant advancements on the horizon for frontline treatment in NDMM and key takeaways from recent clinical trial data that may impact clinical practice.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Key Considerations and Patient Factors in Frontline Therapy Selection for Transplant-Ineligible NDMM Patients

EP. 2: Brief Overview of MAIA, IMROZ, BENEFIT, and CEPHEUS Clinical Trials

EP. 3: Impact of Clinical Trials on the Treatment Landscape for TIE NDMM and Decision-Making Between Triplet vs Quadruplet Therapy

EP. 4: Optimizing Regimens and Managing Adverse Events in TIE NDMM

EP. 5: Looking Ahead and Key Takeaways

EP. 6: Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients

EP. 7: Overview of PERSEUS, IsKia, and GMMG-HD7

Now Viewing

EP. 8: Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM

Please comment on the most reported adverse events in TE patients undergoing triplet or quadruplet therapy.
What do you see as the most significant advancements on the horizon for frontline therapy in TE NDMM?
What are your key takeaways from the latest clinical trial data, and how do you anticipate these findings will impact your day-to-day clinical practice?